The DILITRAIN™ outsourced service makes early, high-acuity assessment of hepatotoxic risk cost-effective for smaller organizations and thereby brings new illumination to the challenge of reducing late-stage candidate attrition. DILITRAIN™ results are generated on HµREL® microlivers, which in peer-reviewed studies have been shown to provide predictive sensitivity and accuracy superior to that of both 3D spheroidal primary hepatocyte cultures and hepatoma cell lines.
$975 per compound is the delivered cost for DILITRAIN™ data. There is no minimum on the number of compounds a client may have tested at one time. DILITRAIN™ is intended to be implemented at the early lead selection stage of preclinical discovery/development—i.e., at roughly the same time as such other basic panels as solubility and Herg assays—so as to minimize the production burden on synthetic chemistry. DILITRAIN™ entails a 14-day repeat-dosing protocol with ATP readout on Days 2 and 14. Total study turnaround time, from receipt of sample to data delivery, is 21 days.